- · 《中国慢性病预防与控制[10/30]
- · 《中国慢性病预防与控制[10/30]
- · 《中国慢性病预防与控制[10/30]
- · 《中国慢性病预防与控制[10/30]
- · 《中国慢性病预防与控制[10/30]
- · 《中国慢性病预防与控制[10/30]
- · 中国慢性病预防与控制版[10/30]
阿德福韦酯联合拉米夫定治疗慢性乙肝和肝硬化(3)
作者:网站采编关键词:
摘要:[6]中华医学会传染病与寄生虫病学分会、肝病学分会联合修定.病毒性肝炎防治方案[J].中华肝脏病杂志,2000,8(6):324-326. [7]Levey AS,Stevens LA,Schmid CH,
[6]中华医学会传染病与寄生虫病学分会、肝病学分会联合修定.病毒性肝炎防治方案[J].中华肝脏病杂志,2000,8(6):324-326.
[7]Levey AS,Stevens LA,Schmid CH,et al.A New Equation to Estimate Glomerular Filtration Rate [J].Ann Intern Med,2009May 5,150(9):604-612.
[8]Izzedine H,Hulot JS,Launay-Vacher V, safety of adefovir dipivoxil in patients with chronic hepatitis B:two double-blind,randomized,placebo-controlled studies[J].Kidney Int,2004,66(3):1153-1158
[9]刘秋霞,王磊,刘峰.慢性HBV感染患者长期服用阿德福韦酯与肾性低磷血症的相关因素[J].山东大学学报:医学版,2017,55(7):73-78.
[10]田敬华,何艳群,马小艳,等.慢性乙型肝炎患者在阿德福韦酯治疗期间的肌酐和血磷水平变化 [J].中华肝脏病杂志,2013,21(3):239-240.
[11]何顺梅,张尧,吕朝阳,等.ADV致Fanconi综合征并继发低磷性骨软化症4例[J].复旦学报:医学版,2014,41(3):374-379.
[12]European Association for the Study of the 2017 clinical practice guidelines on the management of hepatitis Bvirus infection[J].JHepatol, 2017,67(2):370-398.
[13]Terrault NA,Lok ASF,McMahon BJ,et on prevention, diagnosis, and treatment of chronic hepatitis B:AASLD 2018 hepatitis B guidance [J].Hepatology,2018,67(4):1560-1599.
[14]Kayaaslan B,Guner effects of oral antiviral therapy in chronic hepatitis B[J].World JHepatol,2017,9(5):227-241.
[15]Tsai MC,Chen CH,Tseng PL,et of renal safety and efficacy of telbivudine,entecavir and tenofovir treatment in chronic hepatitis B patients:real world experience[J].Clin Microbiol Infect,2016,22(1):
[16]Gara N,Zhao X,Collins MT.Renal tubular dysfunction during long-term adefovir or tenofovir therapy in chronic hepatitis B [J].Aliment Pharmacol Ther,2012,35(11):1317-1325.
[17]Lian JS,Zhang XL,Lu YF,et Lamivudine with Adefovir Dipivoxil Combination Therapy to Entecavir Monotherapy Provides Better Viral Suppression and Kidney Safety[J].Int JMed Sci,2019,16(1):17-22.
[18]赖玺杰,连江山,陈涧阳,等.拉米夫定和阿德福韦酯初始联合治疗慢性乙型肝炎和乙型肝炎肝硬化患者替换为恩替卡韦单药治疗的疗效和安全性观察[J].中华肝脏病杂志,2018,26(2):113-118.
[19]Ze E,Baek EK,Lee JJ,et outcomes of two rescue therapies in lamivudine-refractory patients with chronic hepatitis B:combined lamivudine and adefovir,and 1mg entecavir[J].Clin Mol Hepatol,2014,20(3):267-273.
[20]Zhang Q,Chen J,Pan M,et of replication competence of wild-type and lamivudine-resistant hepatitis B virus isolates from a chronic hepatitis B patient[J].Virus Res,2018,255:165-170.
文章来源:《中国慢性病预防与控制》 网址: http://www.zgmxbyfykz.cn/qikandaodu/2021/0512/917.html